Cargando…
Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach
The COVID-19 pandemic poses an ongoing global challenge, and several risk factors make people with multiple sclerosis (pwMS) particularly susceptible to running a severe disease course. Although the literature does report numerous articles on the risk factors for severe COVID-19 and vaccination resp...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036272/ https://www.ncbi.nlm.nih.gov/pubmed/35466211 http://dx.doi.org/10.3390/neurolint14020030 |
_version_ | 1784693487210332160 |
---|---|
author | Immovilli, Paolo Morelli, Nicola Terracciano, Chiara Rota, Eugenia Marchesi, Elena Vollaro, Stefano De Mitri, Paola Zaino, Domenica Bazzurri, Veronica Guidetti, Donata |
author_facet | Immovilli, Paolo Morelli, Nicola Terracciano, Chiara Rota, Eugenia Marchesi, Elena Vollaro, Stefano De Mitri, Paola Zaino, Domenica Bazzurri, Veronica Guidetti, Donata |
author_sort | Immovilli, Paolo |
collection | PubMed |
description | The COVID-19 pandemic poses an ongoing global challenge, and several risk factors make people with multiple sclerosis (pwMS) particularly susceptible to running a severe disease course. Although the literature does report numerous articles on the risk factors for severe COVID-19 and vaccination response in pwMS, there is a scarcity of reviews integrating both these aspects into strategies aimed at minimizing risks. The aim of this review is to describe the risk of vulnerable pwMS exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the issues related to the SARS-CoV-2 vaccine and to evidence possible future strategies in the clinical management of pwMS. The authors searched for papers on severe COVID-19 risk factors, SARS-CoV-2 vaccination and people with multiple sclerosis in support of this narrative literature review. We propose a multilevel strategy aimed at: the evaluation of risk factors for severe COVID-19 in people with multiple sclerosis, identifying the most appropriate vaccination schedule that is safe for people on disease-modifying drugs (DMDs) and a strict follow-up of high-risk people with multiple sclerosis to allow for the prompt administration of monoclonal antibodies to manage COVID-19 risks in this patient population. |
format | Online Article Text |
id | pubmed-9036272 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90362722022-04-26 Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach Immovilli, Paolo Morelli, Nicola Terracciano, Chiara Rota, Eugenia Marchesi, Elena Vollaro, Stefano De Mitri, Paola Zaino, Domenica Bazzurri, Veronica Guidetti, Donata Neurol Int Review The COVID-19 pandemic poses an ongoing global challenge, and several risk factors make people with multiple sclerosis (pwMS) particularly susceptible to running a severe disease course. Although the literature does report numerous articles on the risk factors for severe COVID-19 and vaccination response in pwMS, there is a scarcity of reviews integrating both these aspects into strategies aimed at minimizing risks. The aim of this review is to describe the risk of vulnerable pwMS exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the issues related to the SARS-CoV-2 vaccine and to evidence possible future strategies in the clinical management of pwMS. The authors searched for papers on severe COVID-19 risk factors, SARS-CoV-2 vaccination and people with multiple sclerosis in support of this narrative literature review. We propose a multilevel strategy aimed at: the evaluation of risk factors for severe COVID-19 in people with multiple sclerosis, identifying the most appropriate vaccination schedule that is safe for people on disease-modifying drugs (DMDs) and a strict follow-up of high-risk people with multiple sclerosis to allow for the prompt administration of monoclonal antibodies to manage COVID-19 risks in this patient population. MDPI 2022-04-15 /pmc/articles/PMC9036272/ /pubmed/35466211 http://dx.doi.org/10.3390/neurolint14020030 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Immovilli, Paolo Morelli, Nicola Terracciano, Chiara Rota, Eugenia Marchesi, Elena Vollaro, Stefano De Mitri, Paola Zaino, Domenica Bazzurri, Veronica Guidetti, Donata Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach |
title | Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach |
title_full | Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach |
title_fullStr | Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach |
title_full_unstemmed | Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach |
title_short | Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach |
title_sort | multiple sclerosis treatment in the covid-19 era: a risk-benefit approach |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036272/ https://www.ncbi.nlm.nih.gov/pubmed/35466211 http://dx.doi.org/10.3390/neurolint14020030 |
work_keys_str_mv | AT immovillipaolo multiplesclerosistreatmentinthecovid19eraariskbenefitapproach AT morellinicola multiplesclerosistreatmentinthecovid19eraariskbenefitapproach AT terraccianochiara multiplesclerosistreatmentinthecovid19eraariskbenefitapproach AT rotaeugenia multiplesclerosistreatmentinthecovid19eraariskbenefitapproach AT marchesielena multiplesclerosistreatmentinthecovid19eraariskbenefitapproach AT vollarostefano multiplesclerosistreatmentinthecovid19eraariskbenefitapproach AT demitripaola multiplesclerosistreatmentinthecovid19eraariskbenefitapproach AT zainodomenica multiplesclerosistreatmentinthecovid19eraariskbenefitapproach AT bazzurriveronica multiplesclerosistreatmentinthecovid19eraariskbenefitapproach AT guidettidonata multiplesclerosistreatmentinthecovid19eraariskbenefitapproach |